e-SPACE Cardio-Renal-Metabolic 2023
Published: 25 March 2023
1h 2m 16sPart 2 | Session 7 Plenary session 10 – Management of diabetes with kidney disease
1h 3m 10sPart 2 | Session 8 Plenary session 11 – Managing frail and elderly patients
1h 1m 47sPart 2 | Session 9 Plenary session 12 – Managing end-stage disease: focus on QoL
58m 8sPart 1 | Session 1 Plenary session 1 – HFpEF Andrew JS Coats, Giuseppe Rosano, Eberhard Standl, María José Soler, Stefan Anker
51m 57sPart 1 | Session 2 Satellite symposium – SGLT2 inhibitors in cardio-renal-metabolic patients – the perfect fit? (Supported by an educational grant from the Boehringer Ingelheim & Lilly Alliance) Stefan Anker, Paola Fioretto, Michel Jadoul
56m 38sPart 1 | Session 3 Plenary session 2 – SGLT2 updates Andrew JS Coats, Hiddo Lambers Heerspink, Antonio Ceriello, Gianluigi Savarese, Christoph Wanner
31m 38sPart 1 | Session 4 Meet the expert – Management of heart failure in real world clinical practice – insights from the REWOLUTION HF surveys Ewa Jankowska, Andrew JS Coats
58m 54sPart 1 | Session 5 Plenary session 3 – Weight management in CRM disease Luc Van Gaal, Wolfram Doehner, Milton Packer, Carel le Roux, Tammy Lyn Kindel, Ildiko Lingvay
30m 11sPart 1 | Session 6 Meet the expert – Implementation patterns and challenges in HF care: insights from the EVOLUTION HF study (Supported by an educational grant from AstraZeneca) Orly Vardeny, Gianluigi Savarese
1h 6m 3sPart 1 | Session 7 Plenary session 4 – Guidelines implementation for acutely ill patients Stephan Von Haehling, Mehriban Isgandar, Alexandre Mebazaa, Adriaan A Voors, Marat Fudim, Vijay Chopra
58m 41sPart 1 | Session 8 Plenary session 5 – Mineralocorticoids antagonists in CRM disease Javed Butler, Sunil Bhandari, Edgar V Lerma, Faiez Zannad, Janani Rangaswami, Gerasimos Filippatos
25m 15sPart 1 | Session 9 Meet the expert – Single pill combination (SPC) in Cardiorenal metabolic (CRM) disease Stefan Anker, Muthiah Vaduganathan
59m 5sPart 1 | Session 10 Plenary session 6 – Diuretics: old drugs, new data, new approaches Nisha Bansal, Christopher Wilcox, Wilfried Mullens, Areef Ishani, William T Abraham
1h 20sPart 2 | Session 1 Plenary session 7 – CRM drug management in patients with low eGFR and type 2 diabetes John J Atherton, Petar M Seferovic, John GF Cleland, Michael Böhm, Meg Jardine, Daniël van Raalte
43m 41sPart 2 | Session 2 Satellite symposium – Management of CKD without diabetes – SGLT2 inhibitors, the new standard of care (Supported by an educational grant from AstraZeneca) Michel Jadoul, David Wheeler, Pinar Topsever
1h 10sPart 2 | Session 3 Plenary session 8 – Diabetes and cardio-renal disease: the relevance of early treatment with the right drug Peter Rossing, Antonio Ceriello, Francesco Prattichizzo, Apostolos G Tsapas, Melanie Davies, John JV McMurray
31m 5sPart 2 | Session 4 Meet the expert – Management of hyperkalemia in cardiorenal disease ‒ practical guidance and novel therapeutic options (Supported by an unrestricted educational grant by CSL Vifor) Gianluigi Savarese, Jolanta Małyszko
e-SPACE Cardio-Renal-Metabolic 2023 was the third edition of the annual global online conference that explores how leading experts, in cardiology, nephrology, and diabetology, are treating the interrelated diseases.
Course leadership Prof Stefan Anker (Berlin, DE), Dr Javed Butler (Texas, US), Prof Antonio Ceriello (Milan, IT), Prof Tara I Chang (California, US), Prof Ian de Boer (Washington, US), Prof Peter Rossing (Copenhagen, DK) and Prof Shelley Zieroth (Winnipeg, CA) lead an interactive programme of plenary sessions, meet the expert, case discussions and satellite symposium sessions focusing on the patient journey.
For the first time, e-SPACE Cardio-Renal-Metabolic 2023 brought together TMA’s mandate for the delivery of continuing professional development to healthcare professionals to achieve concordance with appropriate treatment plans, alongside KDIGO's mission to improve the care and outcomes of patients with kidney disease worldwide through the development and implementation of global clinical practice guidelines, with Radcliffe Cardiology’s goal to deliver cardiovascular knowledge to best support cardiovascular communities transform theory into practice.
- Review the burden of diabetes, kidney disease and heart failure including morbidity, excess mortality, and reduced quality of life affecting individuals around the world
- Describe the complexity and interlink between the three conditions
- Discuss existing guidelines and best approaches for screening patients
- Review evidence-based management strategies for diabetes, cardiovascular disease, heart failure, kidney disease & obesity including SLGT2i, GLP-1RA, new non-steroidal mineralocorticoid receptor antagonists and other emerging therapies
- Foster cross-collaboration between other cardiorenal / metabolic specialists and primary care physicians and allied health care professionals in order to improve patients outcomes
- General Practitioners (GPs)
- HF Specialists
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.
He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.
Director of the Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St. Boniface Hospital in Winnipeg, CA.
She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba. She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Immediate Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She serves as Co-Chair of Canada’s largest annual heart failure meeting, HF Update and serves as Scientific Planning Committee Chair for the Canadian Cardiovascular Congress hosted by the Canadian Cardiovascular Society. She is currently President-elect of the Federation of Medical Women of Canada.
Professor of Clinical Nephrology
Prof Iain Macdougall is a Professor of Clinical Nephrology at King's College Hospital, London, UK.
He graduated from the University of Glasgow and has worked at the Glasgow Western Infirmary, Cardiff Royal Infirmary and St. Bartholomew's Hospital in London.
Prof Macdougall's sub-specialty interest is the anaemia associated with chronic kidney disease.
John GF Cleland
Professor of Cardiology
Prof John Cleland is a Professor of Cardiology at University of Glasgow, Glasgow, UK.
In 1977, he qualified from the University of Glasgow, completed training at St. Mary's & Hammersmith Hospitals (London) and was awarded a Senior Fellowship by the British Heart Foundation.
His main interests include heart failure, extending from epidemiology & prevention, to Phase II-IV trials and guidelines.
He founded the European Journal of Heart Failure and is Past-Chair of the ESC Working Group on heart failure and British Society for Heart Failure.
Matthew R Weir
Director of the Division of Nephrology
Dr Matthew R Weir is Director of the Division of Nephrology and attending physician at University of Maryland, Maryland, US.
He received his medical degree from the University of Virginia, Charlottesville and has written more than 600 manuscripts and book chapters.
Dr Weir is on the editorial board of 22 journals and is Section Editor of Current Hypertension Reports and Current Opinion in Hypertension and Nephrology, and Associate Editor of Clinical Nephrology and the American Journal of Nephrology.
Professor of Medicine
Prof Paola Fioretto is a Professor of Medicine at University of Padova, Padua, IT.
Her research interest includes the effects of glucose lowering therapies on the development and progression of diabetic kidney disease.
Prof Fioretto started her research on renal physiology in diabetes and during her PostDoc Research Fellowship at the University of Minnesota, she devoted her interest to renal structure and ultrastructure in diabetes.